


Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE				ATTY DOCKET NO. 128497		APPLICATION NO. 10/586,742	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)						APPLICANT(S) Patrice MARCHE et al.			
						FILING DATE September 26, 2006			
OTHER DOCUMENTS									
Examiner Initials	Cite No.	Including name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	1	Lin, A. et al. "The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6," <u>Schizophrenia Research</u> , Vol. 32, pp. 9-15, 1998.							
	2	Stevens, Janice R. "Neuropathology of Schizophrenia," <u>Arch. Gen. Psychiatry</u> , Volume 39, pp. 1131-1139, October 1982.							
	3	Karlsson, Hakan et al. "Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia," <u>PNAS</u> , Volume 98, No. 8, pp. 4634-4639, April 10, 2001.							
	4	Perron, H. et al. "Microbial Agents Triggering Endogenous Retroviruses within Genetic Susceptibility Loci Resulting in Expression of Superantigen and Gliotoxic Molecules: a plausible 'Immunovirogenetic' Cascade Causing Multiple Sclerosis," <u>Mod. Asp. Immunobiol.</u> , Volume 1, No. 5, pp. 198-203, 2001.							
	5	Liu, Yuxin et al. "Dextromethorphan Protects Dopaminergic Neurons against Inflammation-Mediated Degeneration through Inhibition of Microglial Activation," <u>Journal of Pharmacology and Experimental Therapeutics</u> , Vol. 305, pp. 212-218, 2003.							
	6	Morimoto, Kiyoshi et al. "Acute Neuroinflammation Exacerbates Excitotoxicity in Rat Hippocampus <i>in Vivo</i> ," <u>Experimental Neurology</u> , Vol. 177, pp. 95-104, 2002.							
	7	Stoll, G. "Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischemia," <u>Rev. Neurol.</u> , Vol. 158, No. 10, pp. 887-891, 2002.							
	8	Guillemin, Gilles J. et al. "Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease," <u>Redox Report</u> , Vol. 7, No. 4, 2002.							
	9	Kim, Eun Joo et al. "Neuroprotective Effects of Prostaglandin E ₂ or cAMP Against Microglial and Neuronal Free Radical Mediated Toxicity Associated With Inflammation," <u>Journal of Neuroscience Research</u> , Vol. 70, pp. 97-107, 2002.							
	10	Kim, Won-Gon. "Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia," <u>Journal of Neuroscience</u> , Vol. 20, pp. 6309-6316, August 15, 2000.							
	11	Klein, Christine et al. "Association Studies of Parkinson's Disease and <i>parkin</i> Polymorphisms," Letters to the Editor: <u>Annals of Neurology</u> , Vol. 48, No. 1, pp. 126-127, July 2000.							
	12	Licinio, J. et al. "The Role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection," <u>Molecular Psychiatry</u> , Vol. 4, pp. 317-327, 1999.							
	13	Cotter, Robin et al. "Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity," <u>Journal of Leukocyte Biology</u> , Vol. 65, pp. 416-427, April 1999.							
	14	Heese, Klaus. "Inflammatory Signals Induce Neurotrophin Expression in Human Microglial Cells," <u>Journal of Neurochemistry</u> , Vol. 70, No. 2, pp. 699-707, 1998.							
	15	Sasser, L. B. et al. "Subchronic Toxicity Evaluation of Lewisite in Rats," <u>Journal of Toxicology and Environmental Health</u> , Vol. 47, pp. 321-334, 1996.							
	16	Chao, Chun C. "Interleukin-1 and Tumor Necrosis Factor- α Synergistically Mediate Neurotoxicity: Involvement of Nitric Oxide and of <i>N</i> -Methyl-D-aspartate Receptors," <u>Brain, Behavior and Immunity</u> , Vol. 9, pp. 355-365, 1995.							
	17	Chao, Chun C. et al. "Tumor Necrosis Factor-Alpha Potentiates Glutamate Neurotoxicity in Human Fetal Brain Cell Cultures," <u>Dev. Neurosci.</u> , Vol. 16, pp. 172-179, 1994.							
	18	Bal-Price, Anna et al. "Inflammatory Neurodegeneration Mediated by Nitric Oxide from Activated Glia-Inhibition Neuronal Respiration, Causing Glutamate Release and Excitotoxicity," <u>Journal of Neuroscience</u> , Vol. 21, No. 17, pp. 6480-6491, September 2001.							
	19	Obrenovitch, T. P. "Quinolinic Acid Accumulation During Neuroinflammation," <u>Annals New York Academy of Sciences</u> , Vol. 239, pp. 1-10, 2001.							
	20	Law, A. et al. "Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type," <u>Brain Research Reviews</u> , Vol. 35, pp. 73-96, 2001.							
	21	Werner, P. et al. "Glutamate excitotoxicity--a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?," <u>Journal Neural. Transm.</u> , Vol. 60, Supplement, pp. 375-385, 2000.							

Date: May 4, 2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 128497	APPLICATION NO. 10/586,742
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) Patrice MARCHE et al.	
				FILING DATE September 26, 2006	
				GROUP 1648	
	22	Pitt, David et al. "Glutamate excitotoxicity in a model of multiple sclerosis," <u>Nature Medicine</u> , Vol. 6, No. 1, pp. 67-70, January 2000.			
	23	Carlson, Noel G. et al. "Inflammatory Cytokines IL-1 α , IL-1 β , IL-6, and TFN- α Impart Neuroprotection to an Excitotoxin Through Distinct Pathways," <u>Journal of Immunology</u> , Vol. 163, pp. 3963-3968, 1999.			
	24	Wang, Yushan S. et al. "The Bacterial Endotoxin Lipopolysaccharide Causes Rapid Inappropriate Excitation in Rat Cortex," <u>Journal of Neurochemistry</u> , Vol. 72, No. 2, pp. 652-660, 1999.			
	25	Yolken, R. H. "Endogenous Retroviruses and Schizophrenia," <u>Brain Research Reviews</u> , Vol. 31, pp. 193-199, 2000.			
	26	Kleine, Tilmann O. et al. "Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF- α , IL-1 β , IL-6, IL-8," <u>Brain Research Bulletin</u> , Vol. 61, pp. 327-346, 2003.			
	27	Aarli, Johan A. "Role of Cytokines in Neurological Disorders," <u>Current Medicinal Chemistry</u> , Vol. 10, pp. 1931-1937, 2003.			
	28	Vladic, Anton et al. "Cerebrospinal Fluid and Serum Protein Levels of Tumour Necrosis Factor-Alpha (TNF- α), Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R gp80) in Multiple Sclerosis Patients," <u>Cytokine</u> , Vol. 20, No. 2, pp. 86-89, Oct. 21, 2002.			
	29	Miljkovic, Dj. et al. "Nitric oxide metabolites and interleukin-6 in Cerebrospinal fluid from multiple sclerosis patients," <u>European Journal of Neurology</u> , Vol. 9, pp. 413-418, 2002.			
	30	Clerici, Mario. "Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease," <u>Journal of Neuroimmunology</u> , Vol. 121, pp. 88-101, 2001.			
	31	Fedetz, Maria. "The -174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis," <u>Journal of Neurological Sciences</u> , Vol. 190, pp. 69-72, 2001.			
	32	Stelmasiak, Zbigniew et al. "IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients," <u>Med. Sc. Monit.</u> , Vol. 7, No. 5, pp. 914-918, 2001.			
	33	Vandenbroeck, K. "High-resolution analysis of IL-6 minisatellite polymorphism in Sardinian multiple sclerosis: effect on course and onset of disease," <u>Genes and Immunology</u> , Vol. 1, pp. 460-463, 2000.			
	34	Stelmasiak, Zbigniew. "Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients," <u>Med Sci Monit.</u> , Vol. 6, No. 6, pp. 1104-1108, 2000.			
	35	Schonrock, Lisa et al. "Interleukin-6 expression in human multiple sclerosis lesions," <u>Neuroscience Letters</u> , Vol. 294, pp. 45-48, 2000.			
	36	Cornford, Eain M. et al. "New systems for delivery of drugs to the brain in neurological disease," <u>Lancet Neurology</u> , Vol. 1, pp. 306-315, September 2002.			
	37	Schmidt, Jens et al. "Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis," <u>Brain</u> , Vol. 126, pp. 1895-1904, 2003.			
	38	Pardridge, William M. "Blood-Brain Barrier Drug Targeting Enables Neuroprotection in Brain Ischemia Following Delayed Intravenous Administration of Neurotrophins," <u>Adv. Exp. Med. Biol.</u> , pp. 397-430, 2002.			
	39	Watanabe, Satoru et al. "Chemotherapeutic Targeting of Etoposide to Regions of the Brain on the Basis of Polyamine Level," <u>Journal of Drug Targeting</u> , Vol. 10, No. 6, pp. 457-461, 2002.			
	40	Lahiri, Debomoy K. et al. "A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimer's Disease," <u>Current Drugs Targets</u> , Vol. 4, pp. 97-112, 2003.			
	41	Scherrmann, J. M. "Drug delivery to brain via the blood-brain barrier," <u>Vascular Pharmacology</u> , Vol. 38, pp. 349-354, 2002.			
	42	Wang, Jian-Xin et al. "Enhanced brain targeting by synthesis of 3', 5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles," <u>European Journal of Pharmaceuticals and Biopharmaceuticals</u> , Vol. 54, pp. 285-290, 2002.			
	43	Doan, Kelly M. Mahar et al. "Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs," <u>Journal of Pharmacology and Experimental Therapeutics</u> , Vol. 303, pp. 1029-1037, 2002.			
	44	Hosoya, Ken-ichi et al. "Recent advances in the brain-to-blood efflux transport across the blood-brain barrier," <u>International Journal of Pharmaceuticals</u> , Vol. 248, pp. 15-29, 2002.			
	45	Mora, Margarita. "Design and Characterization of Liposomes Containing Long-Chain-N AcylPE, for Brain Delivery: Penetration of Liposome Incorporating GM ₁ into the Rat Brain," <u>Pharmaceutical Research</u> , Vol. 19, No. 10, October 2002.			

Date: May 4, 2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 128497	APPLICATION NO. 10/586,742		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) Patrice MARCHE et al.			
				FILING DATE September 26, 2006	GROUP 1648		
	46	Perron, H. et al. "Herpes simplex virus ICP0 and ICP4 immediate early proteins strongly enhance expression of a retrovirus harboured by a leptomeningeal cell line from a patient with multiple sclerosis," <u>Journal of General Virology</u> , Vol. 74, pp. 65-72, 1993.					
	47	Soldan, Samantha S. "Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA," <u>Nature Medicine</u> , Vol. 3, No. 12, pp. 1394-1397, 1997.					
	48	Haahr, S. "Is Multiple Sclerosis Caused by a Dual Infection with Retrovirus and Epstein-Barr Virus?," <u>Neuroepidemiology</u> , Vol. 11, pp. 229-303, 1992.					
	49	Bergstrom, Tomas et al. "Isolation of Herpes Simplex Virus Type 1 During First Attack of Multiple Sclerosis," <u>Ann. Neurol.</u> , Vol. 26, pp. 283-285, 1989.					
	50	Marx, Christine E. et al. "Cytokine Effects on Cortical Neuron MAP-2 Immunoreactivity: Implications for Schizophrenia," <u>Biol. Psychiatry</u> , Vol. 50, pp. 743-749, 2001.					
	51	Maes, Michael et al. "Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics," <u>European Neuropsychopharmacology</u> , Vol. 10, pp. 119-124, 2000.					
	52	Minagar, Alireza et al.. "The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer's disease, and multiple sclerosis," <u>Journal of the Neurological Sciences</u> , Vol. 202, pp. 13-23, 2002.					
	53	Jeohn, Gwang-Ho et al. "Go6976 Protects Mesencephalic Neurons from Lipopolysaccharide-Elicited Death by Inhibiting p38 MAP Kinase Phosphorylation," <u>Annals New York Academy of Sciences</u> , pp. 347-359.					
	54	Gaser, Christian et al. "Ventricular Enlargement in Schizophrenia Related to Volume Reduction of the Thalamus, Striatum, and Superior Temporal Cortex," <u>American Journal of Psychiatry</u> , Vol. 161, pp. 154-156, 2004.					
	55	Kurtzke, John F. "Disability Rating Scales in Multiple Sclerosis," <u>Annals New York Academy of Sciences</u> , Vol. 36, pp. 347-360, 1984.					
	56	Karlsson, H. et al. "HERV-W-related RNA detected in plasma from individuals with recent-onset schizophrenia or schizoaffective disorder," <u>Molecular Psychiatry</u> , Vol. 9, pp. 12-13, 2004.					
	57	Qiu, Zhihua et al. "Interleukin-6, β -amyloid peptide and NMDA interactions in rat cortical neurons," <u>Journal of Neuroimmunology</u> , Vol. 139, pp. 51-57, 2003.					
	58	Jenner, Peter. "Oxidative Stress in Parkinson's Disease," <u>Annals of Neurology</u> , Vol 53, Supp. 3, pp. S26-S38, 2003.					
	59	Woodland, David L. "Human viral superantigens: to be or not to be transactivated?," <u>Trends in Immunology</u> , Vol. 23, No 5, p. 239, May 2002.					
	60	Pranzatelli, Michael R. "Innovations in Drug Delivery to the Central Nervous System," <u>Drugs of Today</u> , Vol. 35, No. 6, pp. 435-448, 1999.					
	61	Merlo, A. et al. "Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas," <u>Acta Neurochir</u> , Vol. 88, Supp., pp. 83-91, 2003.					
	62	Antony, Joseph M. et al. "Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination," <u>Nature Neuroscience</u> , Vol. 7, No. 10, pp. 1088-1095, October 2004.					
	63	Ng, Phillip C. et al. "Preparation and characterization of the Fab and F(ab') ₂ fragments of aromatase activity-suppressing monoclonal antibody," <u>Steroids</u> , Vol. 62, pp. 776-781, 1997.					
	64	Perron, H. et al. "In Vitro transmission and antigenicity of a retrovirus isolated from a multiple sclerosis patient," <u>Res. Virol.</u> , Vol. 143, pp. 337-350, 1992.					
	65	Serra, C. et al. "Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia," <u>Neurol. Sci.</u> , Vol. 22, pp. 171-173, 2001.					
	66	Zawada, Mariola et al. "MSRV POL Sequence Copy Number as a Potential Marker of Multiple Sclerosis," <u>Polish Journal of Pharmacology</u> , Vol. 55, pp. 869-875, 2003.					
	67	Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis," <u>Journal of Neuroimmunology</u> , Vol. 160, pp. 195-203, 2005.					

Date: May 4, 2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 128497		APPLICATION NO. 10/586,742	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) Patrice MARCHE et al.			
				FILING DATE September 26, 2006		GROUP 1648	
	68	Komurian-Pradel, F. et al. "Molecular Cloning and Characterization of MSRV-Related Sequences Associated with Retrovirus-like particles," <u>Virology</u> , Vol. 260, pp. 1-9, 1999.					
	69	Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," <u>Journal of NeuroVirology</u> , Vol. 11, pp. 23-33, 2005.					
	70	Blazar, Bruce R. et al. "Anti-CD3 _F (ab') ₂ Fragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen," <u>Journal of Immunology</u> , Vol. 159, pp. 5821-5833, 1997.					
	71	Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," <u>Science Reports</u> , Vol. 242, pp. 423-426, October 21, 1988.					
	72	Arakawa, Fumiko et al. "Cloning and Sequencing the V _H and V _K Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," <u>Journal Biochem</u> , Vol. 120, pp. 657-662, 1996.					
	73	Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin," <u>Nature</u> , Vol. 339, pp. 394-397, June 1, 1989.					
	74	Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> , Vol. 256, pp. 495-550, August 7, 1975.					
	75	Galfre, G. et al. "Antibodies to major histocompatibility antigens produced by hybrid cell lines," <u>Nature</u> , Vol. 256, pp. 550-552, August 7, 1975.					
	76	Jiang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of $\text{AF-}\kappa\text{B}$," <u>Journal of Immunology</u> , Vol. 165, pp. 3541-3544, 2000.					
	77	Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," <u>Journal of Neuroscience</u> , Vol. 22, No. 7, pp. 2478-2486, April 1, 2002.					
	78	Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," <u>Journal of NeuroVirology</u> , Vol. 9, pp. 637-643, 2003.					
EXAMINER				/Zachariah Lucas/		DATE CONSIDERED 05/19/2009	
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: May 4, 2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./